Richard Sedrani

SDZ RAD, A NEW RAPAMYCIN DERIVATIVE

W. Schüler, Richard Sedrani, Sylvain Cottens et al. · Transplantation · 1997 · 538 citations

Life Sciences, Immunology, Pharmacology +13

Small-molecule factor B inhibitor for the treatment of complement-mediated diseases

Anna Schubart, Karen Anderson, Nello Mainolfi et al. · Proceedings of the National Academy of Sciences · 2019 · 216 citations · Full text

Medicine, Nephrology, Pharmacology +17

Targeted inhibition of the COP9 signalosome for treatment of cancer

Anita Schlierf, Eva Altmann, Jean Quancard et al. · Nature Communications · 2016 · 204 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Chemical modification of rapamycin: the discovery of SDZ RAD

Richard Sedrani, Sylvain Cottens, Joerg Kallen et al. · Transplantation Proceedings · 1998 · 148 citations

Pharmacy, Medicinal Chemistry, Molecular Biology +9

Discovery of 3-(1<i>H</i>-Indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a Potent and Selective Inhibitor of Protein Kinase C Isotypes

Jürgen Wagner, Peter Matt, Richard Sedrani et al. · Journal of Medicinal Chemistry · 2009 · 134 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17